PremiumCompany AnnouncementsOKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain Okyo Pharma announces plans to accelerate development of urcosimod OKYO Pharma Achieves Key Stability Milestone for Urcosimod PremiumCompany AnnouncementsOKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod Okyo Pharma announces OK-101 officially assigned USAN, urcosimod Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges PremiumCompany AnnouncementsOKYO Pharma Secures $1.4 Million to Boost Ophthalmic Innovations Okyo Pharma receives $1.4M in non-dilutive financing OKYO Pharma to Highlight Innovations at BTIG Conference